<DOC>
	<DOCNO>NCT01150656</DOCNO>
	<brief_summary>RATIONALE : Studying effect obatoclax mesylate cell sample patient cancer laboratory may help doctor learn effect obatoclax mesylate cancer cell . It may also help doctor identify biomarkers related cancer . PURPOSE : This research study study obatoclax mesylate sample young patient acute myeloid leukemia .</brief_summary>
	<brief_title>Obatoclax Mesylate Samples From Young Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine comprehensive gene protein expression profile vitro sensitivity resistance obatoclax mesylate multiple-lineage leukemia ( MLL ) -rearranged cell line primary infant acute myeloid leukemia ( AML ) sample . - Define optimum vitro combination obatoclax mesylate target pro-survival BCL-2 family proteins cytotoxic drug MLL-rearranged leukemia cell line primary infant AML sample . - Identify synergistic combination base pharmacodynamic model simulation construct . - Determine whether combination obatoclax mesylate target pro-survival BCL-2 family proteins cytotoxic drug improve survival xenograft model MLL-rearranged infant AML . OUTLINE : This multicenter study . Obatoclax mesylate activity assess via MTT assay . A priori feature acute myeloid leukemia ( AML ) blast relate apoptosis ATG cell death pathway execution characterize use microarray analysis quantitative real-time ( Q-RT ) PCR . Gene protein expression describe quantified use Q-RT PCR western blot analysis specific time point obatoclax mesylate exposure identify pharmacodynamic biomarkers activity characterize cell death mechanism multiple-lineage leukemia ( MLL ) + AML . The MTT assay perform use obatoclax mesylate-cytotoxic chemotherapy combination determine synergy focus common cytotoxic drug employ AML treatment regimen . Obatoclax mesylate efficacy test therapeutic NOG xenograft model primary MLL+ infant AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) Cryopreserved sample infant AML available PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>childhood acute myeloid leukemia/other myeloid malignancy</keyword>
</DOC>